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Leila Yousefi and Allan Tucker
Abstract
The prediction of the onset of different complications of disease, in general, is
challenging due to the existence of unmeasured risk factors, imbalanced data, time-
varying data due to dynamics, and various interventions to the disease over time.
Scholars share a common argument that many Artificial Intelligence techniques that
successfully model disease are often in the form of a “black box” where the internal
workings and complexities are extremely difficult to understand, both from practi-
tioners’ and patients’ perspective. There is a need for appropriate Artificial Intelli-
gence techniques to build predictive models that not only capture unmeasured
effects to improve prediction, but are also transparent in how they model data so
that knowledge about disease processes can be extracted and trust in the model can
be maintained by clinicians. The proposed strategy builds probabilistic graphical
models for prediction with the inclusion of informative hidden variables. These are
added in a stepwise manner to improve predictive performance whilst maintaining
as simple a model as possible, which is regarded as crucial for the interpretation of
the prediction results. This chapter explores this key issue with a specific focus on
diabetes data. According to the literature on disease modelling, especially on major
diseases such as diabetes, a patient’s mortality often occurs due to the associated
complications caused by the disease over time and not the disease itself. This is
often patient-specific and will depend on what type of cohort a patient belongs to.
Another main focus of this study is patient personalisation via precision medicine
by discovering meaningful subgroups of patients which are characterised as pheno-
types. These phenotypes are explained further using Bayesian network analysis
methods and temporal association rules. Overall, this chapter discussed the earlier
research of the chapter’s author. It explores Artificial Intelligence (IDA) techniques
for modelling the progression of disease whilst simultaneously stratifying patients
and doing so in a transparent manner as possible. To this end, it reviews the current
literature on some of the most common Artificial Intelligent (AI) methodologies,
including probabilistic modelling, association rule mining, phenotype discovery and
latent variable discovery by using diabetes as a case study.
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Intelligent systems, whether biological or artificial, require the ability to make
decisions under uncertainty using the available evidence. Several computational
models exhibit some of the required functionality to handle uncertainty. These
computational models in Artificial Intelligent (AI) and Machine Learning are
judged by two main criteria: ease of creation and effectiveness in decision making.
For example, Neural Networks (NNs) which represent complex input/output rela-
tions using combinations of simple nonlinear processing elements, are a familiar
tool in AI and computational neuroscience. Alternatively, probabilistic networks
(also called Bayesian Networks) are a more explicit representation of a domain
through modelling the joint probability distribution (the probability of all possible
outcomes in a domain). This paper provides a short summary of the previous
methods in Intelligent Data Analysis (IDA) in disease progression, decision making
and probabilistic modelling of patients. It then describes some existing key methods
that can be updated or combined to model multiple diabetes complications in the
presence of unmeasured factors. There is considerable research on predicting dia-
betes, especially Type 2 Diabetes Mellitus (T2DM), complications. Nevertheless,
the previous research of the author is discussed in order to address these issues. In
particular, these previously proposed methods have contributed to the diabetes
literature by explaining unknown risk factors and identifying temporal phenotypes
employing hybrid methods (including descriptive and predictive). These suggested
methodology includes rule-based methods for an explanation of patient subgroups
and a probabilistic framework for modelling data explicitly.
2. Literature review: intelligent data analysis in complex disease
progression modelling
This article reviews the current literature on some of the most common AI
methodologies, including probabilistic modelling, association rule mining, and
latent variable discovery. Intelligent Data Analysis (IDA) is a subcategory of AI that
is focused on data analysis and modelling. These methods are known to be highly
successful in combining advantages of modern data analytics, classical statistics and
the expertise of scientists and experts [1–3]. IDA techniques have already proved
successful in clinical modelling [4]. A large and growing body of literature has
investigated IDA approaches that have shown excellent results modelling cross-
sectional clinical data for classification. There has also been substantial modelling on
longitudinal data using IDA techniques. However, there is still an urgent need to
improve these models to take account of the variability of disease progression from
person to person, and explicitly model the time-varying nature of the disease. Many
studies have attempted to find automated ways of helping clinicians predict disease
progression [5].
For many clinical problems, the underlying structure of unmeasured variables
may play an essential role in the progress of the disease. However, it is still a
relatively unexplored area. Identifying these unmeasured variables as hidden or
latent variables is key. What is more, understanding the semantics behind these
unmeasured risk factors can improve the understanding of the disease mechanisms
and thus better improve clinical decision making. Interpreting these latent variables
is complicated; however, as they may represent different many types of
unmeasured information such as social deprivation, missing clinical data, environ-
mental factors, time-based information or some combination of these. To gain trust
in any AI model, it is mandatory to understand/explain influencing factors of
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disease that guide predictions or decisions. This is because clinicians expect to
understand AI diagnoses to be able to make decisions. There is a great deal of debate
over the importance of explanation in AI models inferred from health data. In
particular, there is a balance that needs to be made between the accuracy of com-
plex deep models such as convolutional neural networks (in predictive strategy)
and the transparency of models (in descriptive strategy) that aims to model data in
a more human way such as expert systems.
A combination of explainable and deep strategies rather than either one of them
alone would have a better prognostic value. Furthermore, in order to obtain a more
accurate and explainable prediction of progression, the predictive models need to be
personalised based on how an individual patient matches historical data by identi-
fying patient subgroups.
3. Probabilistic model for time-series analysis
Understanding the pattern of complications associated with the disease has been
used significantly in the clinical domain [6]. It provides an insight into the predic-
tion and relative prevention of the associated complications which are expected to
occur in a patient follow-up [7]. It generally can lead to less suffering time for
patients while saving time and cost to healthcare. However, that is highly depen-
dent on the stage of disease along with the prior occurring complications, which is
associated with time-series analysis. In time-series analysis, every disease risk factor
and complication is determined by various features in previous patient visits (time
interval). At every medical visit, all diabetic patients have a unique profile of
symptoms and complications that change over time, regardless of the phase of the
disease. This non-stationary characteristic of clinical data collected as part of the
monitoring of T2DM creates a difficult context for effective forecasting [8]. Clinical
data needs to be considered as time-series data in order to provide a description of
the progression of a disease over time. Nevertheless, dealing with time-series
patient records is known to be a major issue in the prognosis of comorbidities [9],
particularly when time-series data is imbalanced and contains few examples of
patients without comorbidities that are common to all patients. In Type 2 Diabetes,
for example, once patients are diagnosed with T2DM, half of them show signs of
complications [10]. Unfortunately, these life-threatening complications remain
undiagnosed for a long time because of the hidden patterns of their associated risk
factors [11]. If T2DM is not appropriately managed, the development of serious
complications, such as neuropathy, retinopathy, and hypertension lead to disability,
premature mortality and financial cost [12]. The prediction process is complex due
to the interactions between these complications and other features, as well as
between complications themselves. More importantly, each patient has a unique
profile of complication occurrence and the status of T2DM risk factors during a
patients time-series is subject to change, as their levels may rise and fall over time.
Early diagnosis and prevention techniques are needed to reduce the associated
mortality and morbidity caused by T2DM complications [13]. Although there are
various methodologies for T2DM prediction, for example, risk-prediction equation
and Markov models [14], studies that enable early predictions of diabetes using
predictive models are limited [15]. The risk-prediction equations suffer from
uncertainty as well as performing only one-step-ahead predictions, while Markov
models are limited to a small number of discrete risk factors. Other existing litera-
ture on investigating the prognosis of T2DM complications [16, 17] focuses partic-
ularly on logistic regression and Naive Bayes. Such studies are unsatisfactory for
modelling the complex T2DM complications/risk factors. Logistic regression does
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not perform well when there are multiple or non-linear decision limitations. In
Naive Bayes, there is an assumption of independence among the risk factors
whereas all features are independent of one another.
The major limitation of the previous work in T2DM literature derives from time
discretisation in temporal time slices per year. Therefore, in this study, we consider
all T2DM patient’s follow-up visits regardless of year basis while precisely monitor-
ing the location of change within the unequal number of visits. This chapter sug-
gests that AI in Medicine can provide useful techniques to analyse patient data to be
able to find cure for the disease or reduce patient’s suffering time (see Figure 1).
3.1 Dynamic Bayesian networks
In the field of medical informatics, probabilistic IDA techniques are exploited to
obtain different clinical solutions. To improve patients’ quality of life, there is an
urgent need to extend and explore probabilistic IDA methods to investigate the
disease complications from a clinical point of view. Thus, a Bayesian Network (BN)
decision model was exploited in [18] for supporting the diagnosis of dementia,
Alzheimer disease and mild cognitive impairment. Bayesian Network models
appear to be well suited T2DM progression modelling, because of their flexibility in
modelling spatial and temporal relationships as well as their ease of interpretation
[19]. It has been reported that Dynamic Bayesian Networks (DBNs) are simple BNs
for modelling time-series data and popular for modelling uncertain noisy time-
series clinical data [20]. More importantly, DBNs are probabilistic graphical models
that can handle missing data and hidden variables.
Previous work on learning DBNs have inferred both network structures and
parameters from (sometimes incomplete) clinical datasets [20]. For example, a
recent study presented a DBN method but to analyse fisheries data [21]. Authors in
[22] proposed a Bayes Network to predict diabetes on the Pima Indian Diabetes
dataset. However, the study failed to consider the time-series analysis. Similarly,
authors in another study [23] simulated the health state and complications of type 1
diabetes patients by using partially and entirely learned Bayesian models. Apart
from using a different type of Diabetes, this chapter is utilising a different approach
from the above studies for the representation of the relationship between T2DM
Figure 1.
The organs/muscles affected by the common complications associated with type 2 Diabetes.
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risk factors. Many diseases involved structural changes based upon key stages in the
progression, but many models did not appear to take this into account. There has
been some work in extending DBNs to model underlying processes that are non-
stationary [24]. In [24], clinical features were modelled using a second-order time-
series model while time-invariant temporal dependencies were assumed. Among
this, some studies, for example, Marini and co-authors conducted research [23] that
variables were connected within two-time-series and within the same time slice
assumed that the temporal dependencies were time-invariant. In addition, in
Marinis paper for learning the network structures, a Tabu search was used based on
the Hill climbing algorithm for Bayesian Networks but with no use of latent vari-
ables. However, the approach was useful for stratifying patients according to the
probability of developing complications, the major limitation of the Marinis work
derived from time discretisation in time slices of one year.
Another work in [25] retained the stationary nature of the structure in favour of
parameter flexibility, arguing that structure changes lead almost certainly to over-
flexibility of the model in short time-series. Alternatively, a paper [26] formalised
non-stationary DBN models and suggested MCMC sampling algorithm for learning
the structure of the model from time-series biological data. Similarly, authors in
[27] estimated the variance in the data structure parameter with an MCMC
approach, but the search space was limited to a fixed number of segments and
indirect edges only, which is not suitable for T2DM data. Such studies remained
narrow and limited by constraints on one or more degrees of freedom: the segmen-
tation points of the time-series, the parameters of the variables, the dependencies
between the variables and the number of segments and the ignorance of the incom-
plete data and latent variable.
3.2 Dealing with time-series imbalanced data
Another common problem with classifying complications in longitudinal data is
that there may be many more cases where the complication does not manifest
compared to those where it does. Early prediction of T2DM complications while
discovering the behaviour of associated aggressive risk factors can help to improve a
patients quality of life [28]. This study suggests that while there is an association
between the latent variable and joint complications in the prognosis of T2DM
patients, this relationship is complex. In T2DM data analysis, another challenge can
be to classify/group patients in imbalanced clinical data with several binary com-
plications. Models of the time-series data are needed to manage diabetic complica-
tions and deal with their imbalanced and complex interactions. In particular,
mining time-series is one of the challenging problems in the prognosis of disease. In
addition, it has received considerable critical attention in data mining especially
when there are rare positive results [29]. It has been reported that a class imbalance
in the training data caused by one class (here positive cases) massively outnumbers
the examples in another class (negative class) [30]. This situation may occur where
the number of positive clinical test results for a complication is not equal or even
close to the number of negatives. That can be solved by applying an appropriate
balancing strategy in a multi-class classification problem. Different learning tech-
niques deal with imbalanced data, such as oversampling, undersampling, boosting,
bagging, bootstrapping, and repeated random sub-sampling [31]. Therefore, this
chapter in order to prepare T2DM data for the prediction has utilised these
strategies and customised them based on dataset nature (time-series patients
records with the unequal number of visits). As a result, various balancing strategies
such as pair-sampling, bootstrapping undersampling and over-sampling have
been proposed in [32, 33].
5
Predicting Type 2 Diabetes Complications and Personalising Patient Using Artificial…
DOI: http://dx.doi.org/10.5772/intechopen.94228
The bootstrap approach can be used to identify the significant statistics from
classifiers learnt from such data. For example, in a study [34], Li and co-authors
provide an extension to the temporal bootstrap approach while applied on cross-
sectional data. Similarly, a study conducted in [21], the bootstrap strategy is
extended to longitudinal data by sampling pairs of time points, thus enabling the
(first-order) temporal nature of the data to be inferred. However, these solutions
only can be applicable when the imbalance ratio for all binary complications is
similar. Otherwise, it can be more difficult if we need to over-sample one class value
and under- sample others in order to reduce bias from data. Overall, the observed
balancing strategies from the prior studies have not been sufficient for analysing
more than one complication at a time, whereas it was almost impossible to obtain a
satisfactory prediction performance enhancement for all complications. As well as
modelling unmeasured factors, hidden variables can also be used to model non-
stationary processes. This chapter attempts to address this issue by using hidden
variables discovery approaches based upon T2DM risk factors/complications
dependencies. Before explaining these strategies, it is necessary to understand
unmeasured variables and analyse their dependencies that are generated by causal
structures.
3.3 Causal structure learning and latent variable discovery
Various studies on longitudinal data sets have suggested an association between
complications and risk factors of the disease. To discover probabilistic dependencies
given clinical data, it is necessary to search the space of belief networks or casual
models, which is called casual discovery of BNs [35]. These patterns of dependency
with no model based solely upon the observed variables can be explained by using a
latent variable. The casual discovery indicates dependencies that are generated by
casual structures with unmeasured factors, i.e., hidden variables. Hidden variable
modelling, introduced in [36], has a long tradition in casual discovery. One of the
research gap in the previous literature of disease prediction is the existence of the
unmeasured or latent variables. This is because clinicians cannot measure all risk
factors and carry out all kinds of tests, so there are some unmeasured factors that
clinicians fail to measure, which need to be discovered at the early stage of diabetes.
Furthermore, Factor Learning (FL) was introduced in [37], which has been
known as one method for learning a probabilistic model from data. It can also be
helpful to understand latent variables and measure their hypothetical impacts. FL
contrasts with most other BN learning methods in that it learns a factor structure.
As Martin and co-authors in [37] stated that FL for hidden variables could identify
the most probable structures of factors have given the data and suitable priors.
However, with a large number of variables, FL methods might be prohibitively
expensive. Again in the same research these authors provided a factor structure for
learning methods that efficiently utilised hidden variables. Factor structure indi-
cates the joint probability distribution among discrete observed variables. It also
contributes an explanation across a small number of variables. Although factor
structures are suitable for polynomial time inference, they can cause a reduction in
the prediction accuracy and precision; they contribute an explanation across a small
number of variables. Nevertheless, these techniques failed to consider prior belief in
the factor structure, and therefore, it could be hard to rely on the final structure.
Factor structure indicates the joint probability distribution among discrete
observed variables. Interestingly, each factor in a factor structure corresponds to a
completely connected dependency graph. Although they are suitable for polynomial
time inference, caused reducing accuracy and precision. By contrast, they are not
able to decide precisely whether or not latent variables are present, and in
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consequence there has been some controversy about that status of exploratory
versus confirmatory factor analysis. In this regard, casual discovery methods in AI
have the advantages as they can discover the actual dependencies and indepen-
dencies in the data.
The causal discovery of BNs is a critical research territory, which depends on
looking through the space of causal models for those which can best clarify a pattern
of probabilistic conditions appeared in the data [35]. As a result, [38] showed the
integration of structure-search algorithm with a latent variable in a DBNs model.
However, the method did not consider the discovery of the long-range dependen-
cies with an equal number of time slices. Similarly, in [39], Bayesian belief networks
was used to find the most probable structure, using the K2 algorithm, while adding
a hidden variable. Nevertheless, Cooper in [39] applied the K2 method that needs an
ordering on the nodes. Witting focused on using hidden variables in a known
structure [40]. Cooper in [39] used Bayesian techniques to find the most probable
structure and can use this technique to add hidden variables. In principle, exact
Bayesian methods for hidden variables could identify the most probable structures
of factors given the data and suitable priors. However, with a large number of
variables, exact methods are prohibitively expensive. Furthermore, in [41] Silva
highlighted the weakness of DAG (Directed Acyclic Graph) models in the
marginalisation of Hidden factors and representing the independencies over a sub-
set of features in a DAG with more links. They suggested that Directed mixed
graphs (DMGs) are a solution to this drawback. Therefore, they represented how to
perform Bayesian inference on two DMGs, such as Gaussian and Probit, which is
not the focus of this chapter. Nevertheless, such studies remained narrow and
limited by constraints on one or more degrees of freedom: the segmentation points
of the time-series, the parameters of the variables, the dependencies between the
variables and the number of hidden factors. As a result, Chicharro in [42] analysed
causal influences to find the relationship among different brain regions in several
disorders. Similar to this chapter, Chicharros research made use of Inductive Cau-
sation (IC*) algorithm in the latent process to analyse Granger causality and
Dynamic Causal Modelling. However, Chicharros study did not consider DBNs to
understand causal influences.
Difficulties arise, however, when an attempt is made to implement a Bayesian
Network structure as authors in [43] have argued that the number of potential
DAGs over the disease risk factors is super-exponential. Additionally, the real
cause-effect relationship DAG is not distinguishable while from equivalent struc-
tures when learning only using from observational data. This issue will be worse,
especially when each expert has a unique probability of correctly labelling the
inclusion or exclusion of edges in the disease structure. As noted by Amirkhani [43],
some scoring functions are provided with that score each suitable graph based on
the data and experts knowledge. Another research in [44] shows that networks with
the fixed structure containing hidden variables can be learned automatically from
data using a gradient-descent mechanism similar to that used in neural networks. A
few algorithms have been created to understand the structure for Bayesian Net-
works from both fully observed models and those with hidden variables. Structure
Expectation–Maximisation (SEM) has been produced for learning Probabilistic sys-
tem structure from information with latent factors and missing data. A structure
learning algorithm has been created for non-stationary dynamic probabilistic
models. For example, REVEAL (REVerse Engineering ALgorithm) has been utilised
as a structure learning algorithm, that learns the optimal set of parents for each
node of a network independently, based on the information-theoretic concepts of
mutual information analysis. However, the two-stage temporal Bayes network
(2TBN) cannot be well recovered by the application of REVEAL. A normally
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utilised structure learning algorithm depends on REVEAL which takes in the ideal
arrangement of guardians for every hub of a system autonomously, in light of the
theoretical data ideas of common data examination. Be that as it may, the two-
arrange fleeting Bayes organise as the 2TBN which cannot be all around recuperated
by use of REVEAL. Rijmen in [45] exploited an HMM to study the temporal pattern
of symptoms burden in brain tumour patients. He showed that the discovery of
symptom experience over time is necessary for treatment and follow-up of patients
with symptom-specific intervention. In general, Bayesian learning methods could
determine network structure and how the networks variables should be represented
along with the causal links among them. Moreover, it addressed the difficulty of
qualifying causal relationships in terms of Conditional Probability Tables (CPTs).
Witting focused on using hidden variables in a known structure [40] as the knowl-
edge of the latent variable in predictive modelling is important for an understanding
of the complex AI models. Discovering latent variables can potentially capture
unmeasured effects from clinical data, simplifying complex networks of interac-
tions and giving us a better understanding of disease processes. In addition, it can
improve classification accuracy and boost user confidence in the classification
models [46]. Elidan and co-authors in [47] emphasised the importance of the
presence of hidden variables. In addition, they determined a hidden variable that
interacted with observed variables and located them within the Bayesian Network
structure. They also showed that networks without hidden variables are clearly less
useful because of the increased number of edges needed to model all interactions,
which caused overfitting. Despite the productivity of exploring trees of hidden
variables to render all observable variables independently [48], these hidden vari-
ables were non-optimal with independencies among observable variables. Overall,
previous works on learning DBNs have presented both network structures and
parameters from clinical data sets and learning parameters for a fixed network of
incomplete data, in the presence of missing data and latent variables [20]. Much of
the current literature on disease prediction have argued that a complex AI model,
with many unexplainable hidden variables, also has several serious drawbacks.
Therefore, this chapter has chosen AI DBNs model to learn parameters and latent
variables to predict complications. The next section intends to emphasise the
explainability of the proposed methodology in order to uncover the meaning behind
the latent AI model.
4. Black box models and AI in medicine
Investigating unmeasured risk factors can improve the modelling of disease
progression and thus enable clinicians to focus on early diagnosis and treatment of
unexpected conditions. However, the overuse of hidden variables and lack of
explainability can lead to complex models, which are not well understood (being
black box in nature). Models need to be understood by clinicians to facilitate
transparency and trust.
4.1 Explainability in deep learning
This stage outlines and discusses the limitations of Deep Learning approaches
that have been proposed, so far, to gain deeper insights into the understanding of
black box AI models. AI medical machine such as Deep Learning has become
ubiquitous to provide a high-performance prediction. Nevertheless, understanding
their mechanisms has become a significant concern worldwide whereby the goal is
to gain clinicians and patients trust. The reason behind this is due to several
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obstacles that arise to interpret the findings, such as the scale of big data, complex
interactions, and high-dimensional internal state.
4.1.1 Google’s novel approach
Most medical algorithms proposed by [49], such as AI Doctor designed to
reproduce current problem-solving methods (e.g., the detection of cancers). In
addition, the concept assignment can help people to strengthen their skills and
talents for a computer system that showcased superhuman effectiveness and
efficiency.
Google’s AI Doctor can be demonstrated how they could be used to provide an
explanation further into predictions generated by local classifiers, first from con-
ventional image classification networks to a focused clinical application. The con-
cept attribution approach in AI Doctor offers several promising avenues for future
work. In addition to this, the concept assignment can help people to strengthen
their skills and talents for a computer system that showcases superhuman effec-
tiveness and efficiency. The concepts of explanatory power are outlined by Google
under three principle assumptions/limitations: firstly, comprehension for whatever
hidden layer and artificial neurons would offer. This is based on most of the
information in a deep neural network consists of hidden layers. Secondly, it recom-
mends that acknowledging the numerous hidden layers and understanding their
design on a meta-level would lead to more in-depth modelling. Finally, to comprise
how nodes become active, it considers groups of interconnected neurons that
trigger at the same time and space. These principles are defined instead of
explaining the structural nature of each neuron in each network. This is because the
stratification of a network for the categories of interconnected neurons would
enable its configurations even more abstractable. This is the main weakness of the
black box models.
One of the most highlighted ones is Google’s approach to resolve the
explainability issues while enabling human-like description of the internal state of a
deep network by employing Concept Activation Vectors (CAVs). While medical
systems are mostly designed to reproduce current decision-making methods such as
the classifier used in the detection of cancers, Google has claimed that its novel
strategy can interpret existing clinical data. Although Google has made a claim that
the CAVs can directly relate to one’s anticipated theories, to draw conclusions about
the decision-making process, it needs to consider the human needs of a higher level
of understandability.
Nevertheless, cardiac specialists have been critical of the conclusions derived by
Google in the clinical domain. With the proper information, AI is optimistic that
innovative, unique healthcare insights might be created without human interven-
tion. Unfortunately, this new approach is only established based on extensive and
adequate datasets. This is presumably part of the explanation of why Google has
established projects as its benchmark research proposal is capturing detailed
patients’ history of 100,000 population across four years. However, the investiga-
tion conducted out by Google did not necessarily indicate that the suggestion was
entirely distant. Such as image classifiers that could be applied to low-level struc-
tures. The central concept and assumption are to consider a neural network as
additional assistance that can cause issues related to the internal representation. As a
result, the clinicians commented on the deep explanatory networks. They
questioned the hypotheses, by stating that although the AI algorithms and Deep
Learning could improve current prediction methods of clinical domain, the research
would not be trustworthy unless it had been assessed with caution while a broader
range of disease had been explored. Difficulties arose, when an attempt was made in
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order to implement the principles and these assumptions. It seemed to be evident
that their approach was overconfident and yet to be trusted.
4.1.2 Prototyping examples in Artificial Neural Networks
In order to introduce a different perspective on Deep Learning models’ inter-
pretability, Zintgra and co-authors [50] conducted a study to simplify the black box
structure of Artificial Neural Networks (ANNs). They made use of prototypic
examples method that indicate tools in order to diagnose trained ANNs. In general,
ANNs analyse discrete decision-making processes and obtain high-performance
prediction results.
The prototype examples may be computationally intractable, including a
pre-determined normal distribution to prevent the proliferation of unreasonable
prototype cases. They provided an explanation of tools to train ANNs based on two
datasets. Moreover, it can often be like such a losing battle to describe precisely how
ANNs operate mathematically. Therefore, a much more comprehensive pre-
processing methodology could also be used in a related development (e.g., genera-
tive adversarial network proposed by Goodfellow et al. in [49]). Furthermore,
experimental results and hypotheses in ANNs were portrayed and tested only on
two datasets. Alternatively, a more detailed analysis is required to rely on the
empirical results, which might be achieved by including rich data containing
imbalance issue, different types of features. Selection bias was another potential
concern because it could involve possible measurement errors. It could be extended
through more set of data with various features. Finally, conclusions and interpreta-
tions of data were drawn from an inevitably subjective mechanism on the investi-
gator’s basis. This was because to examine whether the produced case studies should
satisfy the investigator’s standards about the phenomena of been modelled (e.g.,
decisions could be only made by the time it came). This was established based on
approaches or standards for collecting and analysing concepts that might be more
unbiased. As a result, this could also enable investigators/analysers to understand
the implications and weaknesses of the use of ANNs for the discrete decision-
making process, which might enhance the strictness of the approach. However,
many healthcare methods are required to reconstruct conventional prediction
methods (e.g., the identification of cancers), but so far, different ideas to interpret
previous clinical records have been discovered.
4.1.3 Visualisation in deep learning
For the time being, the possibility of an AI physician planning to roll new
prognosis without direct human intervention is a significant distance in which the
more presumably in decades rather than a few years later. Recent developments in
several technologies in the Deep Learning area have been powered by the steadily
declining expense of computing and storage. That being said, realistic apps, includ-
ing certain integrated smartphone and electronic devices, have intensified
explainability issues for Deep Learning in the black box resource-limited environ-
ments. Liu et al. in [51] introduced the leading solution to address these issues
where a deteriorated image of Binary Convolutionary Networks caused by
binarising Filtres. They offered a range of Circulant Filtres (CiFs) and a Circulant
Binary Convolution (CBConv) to strengthen efficiency and to tackle those limita-
tions for Binary Convolutionary functionalities through their proposed Circulant
Backpropagation (CBP). Then, CiFs effortlessly was integrated into the current
deep neural networks (DCNNs). Enormous research has indicated that perhaps the
output difference among one-bit and total-precision DCNNs could be reduced by
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extending the variety and distributing the filtres. Zintgraf et al. in [52] identified
numerous tools to test the model and understand how DCNNs could provide a
reliable outcome by using the visualisation method.
Overall, the existing explanatory Deep Learning approaches would need to be
adapted for further sophisticated longitudinal modelling strategy (rather than with
a multivariate distribution). This would result in better outcomes, for example, in
pixel values which could be estimated reliably by everyone’s environment while it
skewed down much more. By providing the black box models with sufficient data,
machine learning seemed to be overconfident that completely different health
knowledge could then be generated without user intervention. The black box
models of Deep Learning can be simplified in several aspects. For example, if an
object is detected, an image detection machine can breakdown back and towards
specific attributes including shape, colour and texture of the image, and then reduce
the predictions to a mathematical method by checking the classification error and
then background diffusion to improve the practises. In particular, in the world that
it is possible to fully allocate decision making to computer systems, confidence in AI
systems will be hard to achieve. In the future work, one approach that can be
applied to the small-sized T2DM dataset can be the use of Bayesian Neural Net-
works, which will deal with uncertainties in data and model structure by exploiting
the advantages of both Neural Networks and Bayesian modelling. To conclude, AI
can improve current methods of medical diagnosis in terms of interpretability but
cautioned that the technology would need to be more evaluated to be trusted by
both patients and practitioners.
In black box models, it can be challenging to determine what is coordinating the
visible patterns. Such models are problematic not only for lack of transparency but
also for possible biases inherited by the algorithms from clinicians mistakes [53].
This issue is caused based on the human errors and biased sampling of training data
as well as the underestimation of the impact of the risk factors underlying behav-
iour/pattern. In general, as observed from prior studies, it is difficult to obtain
performance enhancement while simultaneously trying to explain hidden factors.
Lakkaraju in [54] suggested that there is a trade-off between patient personalisation
(in a descriptive analysis) and prediction performance (in predictive analysis).
Generally speaking, an improvement in explainability is often possible through a
less accurate model or at a higher cost of the predictive accuracy (in a Black box
model) [6]. There are quite few research studies on predicting T2DM complications
and T2DM black box models. However, studies on explaining an unknown risk
factor/latent phenotype by using a hybrid data mining methodology (including
descriptive and predictive) are rare to find in literature. Therefore, this study
attempts to open the AI, black box model by using both predictive and descriptive
strategies.
5. Patient personalisation and explanation
Most of the previously published studies in diabetes prediction have tended to
focus on all patients as one integrated database rather than separating patients [16].
It can be challenging to stratify patients based on their longitudinal data in order to
determine what is triggering the visible patterns that may be specific to one cohort
of patients. There is some research, such as [55] that assesses the disease prediction
performance based upon different IDA techniques. For example, the onset of the
disease is modelled in [56] while other studies focus on patient modelling [57].
The approach described in this chapter aims to personalise patients by using
unsupervised methodologies to group time-series patient data.
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The proposed descriptive strategy in this chapter has been regarded as a useful
tool known as association rules to detect interesting relationships among T2DM
complications.
5.1 Time-series clustering
Time-series clustering is often problematic [58], especially when we need to
analyse risk factors from matching patterns across time. The literature on time-series
clustering and pattern discovery has highlighted several studies [59]. There have been
some qualitative measures for clustering time-series data, which captured similar risk
factor patterns in dynamic temporal data, regardless of whether the correlation
between them was linear or not [60]. However, they did not seem to be very suitable
for a long and an unequal number of time-series data (e.g., T2DM data). For instance,
authors in [59] proposed an algorithm to cluster patients based on clinical data whilst
utilising the clustering information for identifying distinct patterns. Altiparmak in
[59] provided a slope-wise comparison method (SWC) to find the correlation
between local distance vectors of patients visits, and group clinical test results into
different sub-groups, based upon the related risk factors, by using feature selection.
In their method each cluster of patients was considered as a transaction data that
included a pattern indicating which cluster belonged to each patient. Authors in [61]
used a similar method [59] in clustering, but they clustered fixed length time-series.
Ceccon and coauthors [62] exploited a variation of the naive Bayes classifier with a
hidden variable for segmenting patients into disease sub-types. Ceccon’s study
intended to enhance the classification performance of Glaucoma patients based upon
visual field data. Nevertheless, they only focused on standard/static BNs (instead of
DBNs) to infer the parameter in a cross-sectional dataset. Moreover, they failed to
analyse the influences of multiple hidden variables on the prediction results.
5.2 Pattern discovery and association rules mining
It has previously been observed that patients with T2DM are also at an increased
risk of microvascular comorbidities, including nephropathy, neuropathy, and reti-
nopathy [63]. The underlying pattern of T2DM complications and how their co-
occurrence is followed/caused/related by other complications associated with the
disease, known as the major source of mortality and morbidity in T2DM [64]. That
is because predicting a target complication can be challenging without the consid-
eration of the effects of its associated complications. Similar to Diabetic type 1
patients, although genetic factors impact on developing T2DM, it is believed igno-
rance of developing complications harms patients’ life. What is more, T2DM
patients develop a different profile of complications and features, which changes
over time per follow-up visit. One of the most important factors in the high number
of dependencies among T2DM features and complications is the appearance of
unmeasured risk factors. Surprisingly, the effect of understanding unmeasured
variables, which play an important role in disease prediction, does not seems that
closely examined.
Understanding these associated patterns has a remarkable actual value and can
significantly being used in the clinical domain [6]. It provides an insight into the
prediction and relative prevention of the associated complications which are
expected to occur in patient followups [7]. It also leads to less suffering time for
patients while saves time and cost to healthcare. However, that is highly dependent
on the stage of disease along with the prior occurring complications, which is
associated with time-series analysis. In time-series analysis, every disease risk factor
and complication is determined by various features in previous patient visits (time
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interval). To better understand the complications of the disease and their effects,
this chapter clusters patient the associated rules among the complications. It
attempts to address this issue and present an informative rules/ordering pattern of
patient behaviour, with an aim to capture the complexities of the associated com-
plications’ over time. The proposed descriptive strategy has been regarded as a
useful tool known as association rules (ARs) to detect interesting relationships
among T2DM complications.
Temporal Association Rules (TARs) [65] is an extension to association rules [66]
to analyse basket data that includes a temporal dimension to order related items.
Many algorithms with temporal rules work by dividing the temporal transitions
database into different partitions based on the time granularity obliged. For exam-
ple, different mining algorithms were reformulated and presented to reflect the
new general temporal association rules. These include Progressive Partition Minder
(PPM), Segmented Progressive Filter (SPF), and TAR algorithm [65–67]. Various
algorithms have been proposed for the incremental mining of temporal association
rules, especially for numerical attributes [68]. Allen’s rules [69] generalised
abstracted time-series data into a relation (PRECEDES) to find TARs in [70].
Various ways were proposed to explore the problem of temporal association rules
discovery [71]. Nevertheless, previous studies performed discovering association
rules on a given subset specified by the time [72], whilst not considering the specific
exhibition period of the elements.
Association Rule Mining (ARM) finds frequent patterns by mining ARs with the
use of two basic parameters of support and confidence [73]. The majority of the
previous ARM algorithms worked by dividing the temporal transitions database
into different partitions based on the time granularity obliged.
Difficulties arise with TARs when there are some rare rules of particular interest
[74]. Many studies have employed the most common filtering metrics rather than
support and confidence in order to detect interesting rules [75]. There is a contro-
versy to this, as a study in the literature argued that a conservative ARM methodol-
ogy only based on a fixed and rigid threshold for the filtering metrics could be
problematic. A few studies attempted to mine frequent underlying patterns of
diabetic complications [76]. The frequent pattern mining research significantly
affects data mining techniques in longitudinal data. A post-processing approach in
[77] attempted to extract interesting subsets of temporal rules within T2DM data.
However, it only considered characteristic patterns of administrative data without
the appearance of latent variables. Other researchers have undertaken association
rule mining of clinical data [78, 79]. Lee et al. attempted to address the issue in [67]
and have led to the proposal of the concept of general TARs, where the items were
allowed to have varying exhibition periods, and their support was made based on
that accordingly. Another research conducted by Plasse et al. in [80] looked at
finding homogeneous groups of variables. They suggested that a variable clustering
method could be applied to the data in order to achieve a better result in pattern
discovering methodology. However, their strategy to mine ARs differed from this
chapter in which the number of rules was reduced only based on hierarchical clus-
tering applied to items, not to multiple identical binary attributes. Among these, some
methods uncovered temporal patterns and relationships among clinical variables,
including causal information [81], numeric time-series analysis [82]. Nevertheless,
considering all of this evidence, none of the above studies has clustered uneven
time-series clinical data based on a hidden variable for extracting temporal pheno-
type and behaviours of patients.
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6. The suggested methodology
This chapter, so far, has described the research gap in the modelling and
explaining of complex disease processes and thus given the motivation behind the
suggested methodology. The previously discussed methods suffer from some limi-
tations in addressing imbalance issues, complex and temporal relationships between
Figure 2.
The proposed hybrid methodology to find explainable subgroup of patients by personalising diabetic patients




(sometimes unmeasured) factors, and the identification of different underlying
characteristics of disease for different subgroups of the population. There is con-
siderable research on predicting T2DM complications. Among these, studies on
explaining unknown risk factors and identifying temporal phenotypes by using
hybrid methods (including descriptive and predictive) are rare to find in literature.
It represented the reason of the earlier research conducted by the author in [32, 33,
83–85]. The current work of this chapter’s author has attempted to address these
issues in the previous research in [32, 33, 84], after describing the case study data as
a starting point, the suggested methodology is explored as a framework for model-
ling real time-series clinical data. In the recent work conducted in [83, 85], the
identification of informative hidden factors is investigated followed by methods to
cluster patients into meaningful subgroups along with the identification of a latent
temporal phenotype and the characterisation of these groups using temporal asso-
ciation rules (as illustrated in Figure 2).
7. Type 2 Diabetes as a case study
The World Health Organisation (WHO) reported that Type 2 Diabetes Mellitus
(T2DM) accounts for at least 90% of all diabetes types. Another study in WHO
revealed that T2DM patients are at increased risk of long-term vascular
comorbidities, which is known as “underlying cause of death” and severe pheno-
type of the disease [86]. It has previously been observed that patients with T2DM
are also at an increased risk of microvascular comorbidities, including nephropathy,
neuropathy, and retinopathy [86]. Similar to Diabetic type 1 patients, although
genetic factors impact on developing T2DM, it is believed ignorance of developing
complications harms patient life because it may develop a different profile of
complications and features, which changes over time per follow-up visit. However,
these life-threatening complications remain undiagnosed for a long time because of
the hidden patterns of their associated risk factors [11]. The underlying pattern of
the complications is known as the major source of mortality and morbidity in T2DM
and how their co-occurrence is followed/caused by other complications associated
with the disease [64]. That is because predicting a target complication can be
challenging without the consideration of the effects of its associated complications.
7.1 Data description
The observed dataset in this chapter is similar to the data utilised in the previous
study of Diabetes patients in [83] of pre-diagnosed T2DM patients aged twenty five
to sixty five years (inclusive) that were recruited from clinical followups at the
“IRCCS Instituti Clinic Scientifici” (ICS) Maugeri of Pavia, Italy. The MOSAIC
project funds the information based on the seventh Framework Program of the
European Commission, Theme ICT201152 Virtual Physiological Human (600914)
from 2009 to 2013. These consists of physical examinations and laboratory data for
complications and risk factors (predictors) in T2DM which were selected supported
existing literature on T2DM [76, 87–90] as well as the recommendations from the
clinicians at ICS. These are Retinopathy (RET), Hypertension (HYP), Nephropathy
(NEP), Neuropathy (NEU) and LIVer disease (LIV) (see Table 1). Here, the pre-
dictors are known and selected from the dataset: Body Mass Index (BMI), Systolic
Blood Pressure (SBP), High-density Lipoprotein (HDL), Glycated Haemoglobin
(HbA1c or HBA), Diastolic Blood pressure (DBP), ChOLesterol (COL), Smoking
habit (SMK) and Creatinine (CRT). Control Values for T2DM risk factors are
classified in Table 2 illustrates three clinical level of risk, particularly low (zero),
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medium (one) and high (two). In T2DM data, the worsening level of the micro-
vascular diseases and HYP is known as a significant cause of death [91]. Even
though micro-vascular complications such as RET, NEP, NEU are less frequent
comparing to HYP, an inadequate estimation of them causes long-term suffering
and life-threatening comorbidities [64]. Fowler and co-authors in [7] researched
type 2 Diabetic American patients. This research utilised T2DM key risk factors
such as HbA1c, SBP, and DBP to investigate relationships among complications
such as HYP, NEP, RET, and NEU. In addition, LIV is a severe phenotype of
diabetes and associated with T2DM complications, especially NEU [92]. Litwak
analysed Russian diabetic patients in [93] which referred to the influence of macro-
vascular and micro-vascular disease on one anther. For example, important features
in T2DM dataset such as blood pressure, HDL, lipid, BMI, and HbA1c influence
diabetic patients’ complications. They also revealed that HDL has a negative effect
on HYP, NEP, NEU, and RET, whereas HbA1c negatively associated with HYP.
Again, a study conducted by Ramachandran [94] referred to the high prevalence of
NEU and RET in Type 2 diabetes in India. Similarly, research in [76] suggested that
most of the diabetic patients have objective evidence for some variety of NEU, but
only a few of them have identified by symptoms. This research also showed that
there is a strong association among NEP, NEU, and RET. This study only concen-
trates on five binary complications as the predictive target classes in a binary
classification problem (with two categories of classes: “high” or “low” risk). Fur-
thermore, a complication class value of low risk (zero) represents a patient visit in
Node ID Target complication Diagnosis outcomea Clinical risk classb
2 Retinopathy (RET) {Negative,Positive} {low,high}
3 Neuropathy (NEU) {Negative,Positive} {low,high}
4 Nephropathy (NEP) {Negative,Positive} {low,high}
5 Liver Disease (LIV) {Negative,Positive} {low,high}
6 Hypertension (HYP) {Negative,Positive} {low,high}
aNegative test result, Positive test result.
bLow clinical risk, High clinical risk.
Table 1.
The description of T2DM target complication, clinical node control values, and discretised states [83].
Node ID T2DM risk factors Control valuea Discretised valueb
1 HbA1c (HBA) 6.6  1.2 (%) {low,medium,high}
7 Body Mass Index (BMI) 26.4  2.4 kg=m2ð Þ {low,medium,high}
8 Creatinine (CRT) 0.9  0.2 mg=dLð Þ {low,medium,high}
9 Cholesterol (COL) 0.9  0.2 mg=dLð Þ {low,medium,high}
10 High-Density Lipoprotein (HDL) 1.1  0.3 mmol=lð Þ {low,medium,high}
11 Diastolic Blood Pressure (DBP) 91  12 mmHgð Þ {low,medium,high}
12 Systolic Blood Pressure (SBP) 148  19 mmHgð Þ {low,medium,high}




The description of the T2DM clinical features, risk factors, control values, and the discretised states [83].
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which the complication is not present; otherwise, it is at high risk (one). For
instance, a complication class value of zero represents a patient visit in which the
complication is not present; otherwise, it is one. Alternatively, other risk factors
associated with a patient (symptoms/clinical tests) are abstracted in the multi-class
classification problems with more than two targets including high, medium, and
low risk patient, according to a diabetes experts definitions [95, 96]. For each
patient in T2DM dataset, time-series analysis is described in Appendix A with
definition of the related notations.
8. Experimental results and conclusions
This section summarises the clinical implications and shows how the obtained
experimental findings in the previous works [83, 84, 97] and their significance have
led to developing explanatory AI models. For example Table 3 illustrated the prom-
ising results obtained by the proposed Stepwise approach discussed in [33, 84].
In Table 4, the prediction performance of the underlying patterns of complica-
tions for these patients within the discovered subgroup dataset (was introduced in
[83] as DS1 and discovered using the descriptive strategy) was analysed and com-
pared to all patients belonged to DS (the raw T2DM dataset). It also suggested that
DS1 (by personalising patients) could be considered as a dataset with less uncer-
tainty than DS. In order to describe the inference problem in this chapter, the causal
Percentage (%) Accuracy Sensitivity Specificity Precision
No Hidden variable in [32] 48 53 48 53
Stepwise IC* in [33] (Step1) 60 40 80 70
Enhanced stepwise in [97] (Step1) 80 51 98 97
Stepwise IC* in [33] (Step2) 78 98 58 68
Enhanced stepwise in [97] (Step2) 95 80 96 86
Stepwise IC* in [33] (Step3) 78 98 58 68
Enhanced stepwise in [97] (Step3) 95 81 96 82
Enhanced stepwise in [97] (Step4) 96 81 97 092
Enhanced stepwise in [97] (Step5) 95 82 97 85
Table 3.
Comparison of our new and enhanced stepwise IC*LS approach in [97] with its previous version (stepwise IC*)










The overall prediction accuracy of T2DM complications for patients in DS is compared to DS1.
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relationships seemed to be a reliable option to represent static and dynamic corre-
lations between T2DM risk factors. The causal inference has a greater focus on
distinguishing causes from other associations than on uncovering detailed temporal
relationships. Therefore, in this work ([83]), several predictive strategies in order to
test whether the descriptive approaches have contributed to improving the predic-
tion performance of the ordering patterns of complications.
8.1 Clinical implications
This study offered several valuable insights into the prediction challenges in
diabetes and similar diseases and explained how they could be tackled. First,
throughout this chapter, appropriate machine learning techniques were conducted
to model complex interactions among the complications, risk factors and
unmeasured factors. For instance, the use of probabilistic graphical models pro-
vided a significant improvement in the accuracy of predictive models while reduc-
ing uncertainty in disease management. Having adopted DBNs to learn hidden risk
factors and effectively understand the AI black box model was the key contribution
of this research. The temporal phenotype was identified to represent the overall
patterns of disease risk factors for each patient based on the discovered hidden
variables over time. The descriptive analytics, in [97], provided valuable insights
into the hidden variable effects on stratifying patients into different sub-groups,
whether or not they developed the same complications. These findings also
explained the influence of the latent variable on the bootstrapped data. Phenotype
discovery was utilised to categorise and investigate meaningful subgroups of
patients based on how an individual matches historical data. The hybrid type
methods in discovering meaningful subgroups and explaining temporal phenotype
also led to a better understanding of clinical data as well as aiding to interpret the
unmeasured factors while demonstrating their risks.
8.2 Future works
The generalisability of the results presented in this study is subject to certain
limitations as follows: This research was conducted to explain and discover the
unmeasured factors with a few patients and relatively few features. Thus, this study
focused on time-series complex clinical dataset like T2DM, which was a small-sized
dataset with an unequal number of patient’s follow-up visits (which is common in
clinical data). This study was specific to T2DM concept and Bayesian modelling;
hence, one fundamental criticism could be the bias towards this dataset and
whether the method could be developed in other fields of clinical data in the future.
In order to help overcome the limitations discussed in the previous section, the
following recommendations are suggested: The originality of the proposed study
consisted in its innovative, analytical, and methodological strategies to predict and
explain complex clinical data to improve patients’ quality of life. A natural progres-
sion of this work for a better generalisability should involve extending the latent
DBNs model with more hidden variables to capture a greater variety of unmeasured
factors to characterise critical changes and produce interesting findings that account
more for better explainability and predictability. In addition, to address the limita-
tion related to the small-sized dataset, this work could be extended to further
investigation and experimentation into clinical impacts and environmental factors,
such as family history, pollution, and glucose. More research also might be
conducted to monitor disease progression effectively and detect the underlying
patterns of complications, which could provide clinicians with a better understand-
ing of the obtained findings. For example, a greater focus on phenotype discovery
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could enable assessment of the long-term effects of the temporal phenotype on the
patient, which might be done by following qualitative approaches to support the
obtained findings from the biomedical literature. The generalisability of the find-
ings obtained in this study might be tested on other data with potentially non-
stationary, complex, and incomplete data. For instance, the pre-processing
approaches, statistical analysis, temporal phenotype, MCI algorithm and the DBNs
model could be applied to another complex data (e.g., COVID-19). Therefore, in a
new project, a similar patient model to this research was mainly employed, which
primarily concentrated on helping healthcare staff in their understanding of how
COVID-19 spread and how they could be better prepared.
In the current work as a Post-Doctorate research fellow at Brunel University and
University City London (UCL) associated with the BHF Alan Turing Institute
jointly funded research project with the collaborators of the project in UCL and
GSK. This project aims to develop a computational tool to investigate the action of
drug compounds for the treatment of cardiovascular disease and type 2 diabetes
which involves: firstly, the construction of a cardiovascular disease (CVD) and
Type-II diabetes (T2D) relevant metabolic measures networks, using repeated
measures. Secondly, the combination of different causal networks on the same set
of metabolic measures. Lastly, the integration to the system of available drug targets
and disease information for testing CVD and T2D drugs.
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